today announced that it has signed agreements with a number of academic organizations
including the Scripps Research Institute, the University of California, San
Francisco, Boston University, Temple University and the University of Texas
at Arlington. These institutions join the top 20 pharmaceutical companies, who
have all deployed ThalesNano's H-Cube.
The H-Cube Hydrogenation Reactor is a bench-top standalone device, uniquely
combining continuous-flow chemistry with endogenous hydrogen generation and
a disposable catalyst cartridge system. At about a foot wide, and with the flexibility
to use a vastly extended range of conditions compared to traditional techniques
without any safety concerns, the H-Cube system is ideally suited to educational
and to academic research laboratories.
Professor Phil Baran of the Scripps Research Institute explains, "The H-Cube
has already had a dramatic effect on our research and that of several groups
at Scripps. We believe the H-Cube will soon be as essential as an HPLC in the
toolkit of a modern organic chemistry laboratory."
Added Dr. Chris O'Brien of the University of Texas at Arlington, "My group
now take for granted that they can perform high pressure, high temperature hydrogenations
with ease in a fume hood. To do these reactions conventionally requires substantial
safety precautions and training. As testament to the H-Cube Midi's ease-of-use
and scalability, high pressure hydrogenations are now routinely performed by
undergraduates to yield 10s of grams of final product. H-Cube technology is
a must-have for any synthetic laboratory."
"We believe that collaboration with leading universities will serve the
entire chemistry community," said Dr. Laszlo Urge, CEO of ThalesNano, Inc.
"These universities are teaching future generations about the alternative
discovery methods and novel environmentally friendly technologies. We are delighted
to work with these institutions who share our common vision of transforming
the way that chemical entities are discovered. Their experience will further
enhance the repertoire of published H-Cube reactions, which will provide great
benefit to our community of academic and commercial users."
Dr. Ferenc Darvas, President and Chairman of ThalesNano, Inc. reflected, "The
fact that our technology is seeing such wide acceptance in academia galvanizes
H-Cube's position as the new paradigm for efficient hydrogenation. These schools
are at the forefront in helping other academic institutions and the industry
to realize the benefits of continuous flow technology in the future."